Edaravone inhibits protein carbonylation by a direct carbonyl-scavenging mechanism: Focus on reactivity, selectivity, and reaction mechanisms

Antioxidants and Redox Signaling

Volumn 12, Issue 3, 2010, Pages 381-392

  Aldini, Giancarlo ^a   Vistoli, Giulio ^a   Regazzoni, Luca ^a   Benfatto, Maria Carmela ^a   Bettinelli, Ilaria ^a   Carini, Marina ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACROLEIN; CARBONYL DERIVATIVE; GLYOXAL; HEMOGLOBIN; NORPHENAZONE; PROTEIN;

ARTICLE; BETA CHAIN; ELECTROSPRAY MASS SPECTROMETRY; GLYCATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; LIPID PEROXIDATION; MASS SPECTROMETER; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; REACTION ANALYSIS; TANDEM MASS SPECTROMETRY;

ALDEHYDES; ANTIPYRINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FREE RADICAL SCAVENGERS; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBINS; MOLECULAR DYNAMICS SIMULATION; PROTEIN CARBONYLATION; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

ACCIPITRIDAE;

EID: 75149193424     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2009.2814     Document Type: Article

References (32)

1. Aldini G, Dalle-Donne I, Colombo R, Maffei Facino R, Mil-zani A, and Carini M. Lipoxidation-derived reactive car-bonyl species as potential drug targets in preventing protein carbonylation and related cellular dysfunction. Chem Med Chem 1: 1045-1058, 2006.
2. Aldini G, Dalle-Donne I, Facino RM, Milzani A, and Carini M. Intervention strategies to inhibit protein carbonylation by lipoxidation-derived reactive carbonyls. Med Res Rev 27: 817-1168, 2007.
3. Balawender R and Komorowski L. Atomic Fukui function indices and local softness ab initio. J Chem Phys 109: 5203-5211, 1998.
4. Butterfield DA and Castegna A. Proteomics for the identification of specifically oxidized proteins in brain: technology and application to the study of neurodegenerative disorders Amino Acids 25: 419-425, 2003.
5. Butterfield DA, Sultana R, and Poon HF. Redox proteomics: a new approach to investigate oxidative stress in Alzheimer's disease. In: Redox Proteomics: From Protein Modifications to Cellular Dysfunction and Disease, edited by Dalle-Donne I, Scaloni A, and Butterfield DA. Hoboken: Wiley, 2006, pp. 563-603.
6. Carini M, Aldini G, and Maffei Facino R. Mass spectrometry for detection of 4-hydroxy-trans-2-nonenal (HNE) adducts with peptides and proteins. Mass Spectrom Rev 23: 281-305, 2004.
7. Crabb JW, O'Neil J, Miyagi M, West K, and Hoff HF. Hy-droxynonenal inactivates cathepsin B by forming Michael adducts with active site residues. Protein Sci 11: 831-840, 2002.
8. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, and Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 329: 23-38, 2003.
9. Dalle-Donne I, Scaloni A, Giustarini D, Cavarra E, Tell G, Lungarella G, Colombo R, Rossi R, and Milzani A. Proteins as biomarkers of oxidative=nitrosative stress in diseases: the contribution of redox proteomics. Mass Spectrom Rev 24: 55-99, 2005.
10. Dalle-Donne I, Aldini G, Carini M, Colombo R, Rossi R, and Milzani A. Protein carbonylation, cellular dysfunction, and disease progression. J Cell Mol Med 10: 389-406, 2006.
11. Domingo LR, Benchoukb W, and Mekellecheb SM. Understanding the role of the Lewis acid catalyst on the 1,3-dipolar cycloaddition of N-benzylideneaniline N-oxide with acro-lein: a DFT study. Tetrahedron 63: 4464-4471, 2007.
12. Fenaille F, Guy PA, and Tabet JC. Study of protein modification by 4-hydroxy-2-nonenal and other short-chain aldehydes analyzed by electrospray ionization tandem mass spectrometry. J Am Soc Mass Spectrom 14: 215-226, 2003.
13. Higashi Y. Edaravone for the treatment of acute cerebral infarction: role of endothelium-derived nitric oxide and ox-idative stress. Expert Opin Pharmacother 10: 323-331, 2009.
14. Izuhara Y, Nangaku M, Takizawa S, Takahashi S, Shao J, Oishi H, Kobayashi H, van Ypersele de Strihou C, and Miyata T. A novel class of advanced glycation inhibitors ameliorates renal and cardiovascular damage in experimental rat models. Nephrol Dial Transplant 23: 497-509, 2008.
15. LoPachin RM, Barber DS, and Gavin T. Synaptosomal tox-icity and nucleophilic targets of 4-hydroxy-2-nonenal. Tox-icol Sci 104: 235-249, 2008.
16. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, Ishikawa N, Nangaku M, and Kurokawa K. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 13: 2478-2487, 2002.
17. Negre-Salvayre A, Coatrieux C, Ingueneau C, and Salvayre R. Advanced lipid peroxidation end products in oxidative damage to proteins: potential role in diseases and therapeutic prospects for the inhibitors. Br J Pharmacol 153: 6-20, 2008.
18. Nielsen JE. Analysing the pH-dependent properties of proteins using pKa calculations. J Mol Graph Model 25: 691-699, 2007.
19. Nyström T. Role of oxidative carbonylation in protein quality control and senescence. EMBO J 24: 1311-1317, 2005.
20. O'Brien PJ, Siraki AG, and Shangari N. Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health. Crit Rev Toxicol 35: 609-662, 2005.
21. Olsen JV, de Godoy LM, Li G, Macek B, Mortensen P, Pesch R, Makarov A, Lange O, Horning S, and Mann M. Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. Mol Cell Proteomics 12: 2010-2021, 2005.
22. Pedretti A, Villa L, and Vistoli G. Modeling of binding modes and inhibition mechanism of some natural ligands of farnesyl transferase using molecular docking. J Med Chem 45: 1460-1465, 2002.
23. Pennathur S and Heinecke JW. Mechanisms for oxidative stress in diabetic cardiovascular disease. Antioxid Redox Signal 9: 955-969, 2007. (Pubitemid 46919596)
24. Poli G, Schaur RJ, Siems WG, and Leonarduzzi G. 4-Hydroxynonenal: a membrane lipid oxidation product of medicinal interest. Med Res Rev 28: 569-631, 2008.
25. Rees MS, van Kuijk FJGM, Siakotos AN, and Mundy BP. Improved synthesis of various isotope labelled 4-hydroxyalkenals and peroxidation intermediates. Synth Commun 25: 3225-3228, 1995.
26. Kind T and Fiehn O. Seven golden rules for heuristic filtering of molecular formulas obtained by accurate mass spec-trometry. BMC Bioinformatics 8: 105-121, 2007.
27. Uchida K. Role of reactive aldehyde in cardiovascular diseases. Free Radic Biol Med 28: 1685-1696, 2000.
28. Vistoli G, Orioli M, Pedretti A, Regazzoni L, Canevotti R, Negrisoli G, Carini M, and Aldini G. Design, synthesis, and evaluation of carnosine derivatives as selective and efficient sequestering agents of cytotoxic reactive carbonyl species. Chem Med Chem 4: 967-975, 2009
29. Watanabe T, Tahara M, and Todo S. The novel antioxidant edaravone: from bench to bedside. Cardiovasc Ther 26: 101-114, 2008.
30. Xi H, Akishita M, Nagai K, Yu W, Hasegawa H, Eto M, Kozaki K, and Toba K. Potent free radical scavenger, edar-avone, suppresses oxidative stress-induced endothelial damage and early atherosclerosis. Atherosclerosis 191: 281-289, 2007.
31. Yocum AK, Yergey AL, and Blair IA. Novel lipid hydroperoxide-derived hemoglobin histidine adducts as bio-markers of oxidative stress. J Mass Spectrom 40: 754-764, 2005.
32. Zhang N, Komine-Kobayashi M, Tanaka R, Liu M, Mizuno Y, and Urabe T. Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain. Stroke 3: 2220-2225, 2005.